Eisai Inc. announced today that the United States Food and Drug Administration (FDA) has approved Halaven? (eribulin mesylate) Injection for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease...
More...